Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuM195 in High Risk Primary MDS
NCT00003984Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 1999
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of lintuzumab in myelodysplastic syndrome (MDS), sponsored by European Organisation for Research and Treatment of Cancer. Planned start Feb 1999; status: withdrawn.
02
Drugs
lintuzumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003984.